The Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) is honored to recognize the achievements of these three promising investigators. The Richard and Mildred Poletsky Award Recipients: The Richard and Mildred Poletsky Education Fund was initiated in 1995 by the family of Mr. Richard Poletsky, a native of St. Louis and alumnus […]
In the past two years, the Food and Drug Administration has approved two novel Alzheimer’s therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease. But while the approvals of lecanemab and donanemab, both antibody therapies that clear plaque-causing amyloid proteins from the brain, were greeted with enthusiasm […]
Remarkably, Doug Whitney, 75, has escaped genetic destiny. Like many members of his family, Whitney inherited a rare genetic mutation that all but guarantees he would develop early-onset Alzheimer’s disease. But Whitney, whose relatives first showed symptoms of cognitive decline in their early 50s, remains mentally sharp with no signs of the devastating disease, and […]
In this episode, Washington University researchers discuss the Food and Drug Administration’s recent full approval of the drug Leqembi (lecanemab) and what it could mean to the future of Alzheimer’s disease treatments. The drug is approved for use in people with mild dementia from Alzheimer’s disease, but researchers at Washington University’s Charles F. and Joanne Knight […]
The Food and Drug Administration (FDA) recently gave full approval to Leqembi (lecanemab) for patients in the early stages of Alzheimer’s disease. Physicians and researchers at Washington University School of Medicine’s Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) in St. Louis were involved in the clinical trials evaluating Leqembi, in which they enrolled […]
Patients who live in less affluent neighborhoods and those from underrepresented racial or ethnic groups are less likely than others to receive specialized care for dementia, including Alzheimer’s disease, a new study from Washington University School of Medicine in St. Louis indicates. Further, the research shows that Black people are more likely than white people […]
Alzheimer’s disease is like two deaths, said Stephanie Griffin, whose father died of the brain disease in 2015. “It’s horrific,” she said. “First, you watch them lose the ability to talk, to think, to do any of the things they used to do. And then, to see them pass because of it? It’s just … […]
Memory loss is often the first sign of Alzheimer’s disease, followed by confusion and difficulty thinking. These symptoms reflect the typical pattern of worsening damage to brain tissues. Toxic clusters of proteins first concentrate in the temporal lobes of the brain — the memory area — before spreading to parts of the brain important for […]
Carlos Cruchaga, PhD, has received a 2022 Zenith Fellow Award from the Alzheimer’s Association. The annual award is given to scientists who have made significant contributions to the field of Alzheimer’s disease research and are likely to make additional, substantial contributions in the future. Funding attached to the fellowships also helps support high- risk, high-reward projects in […]
Investigators at Washington University School of Medicine in St. Louis conduct many clinical trials and translational research studies each year to develop and evaluate new ways of treating and diagnosing myriad types of diseases. Such research holds promise for improving the health of people living in St. Louis, across the state of Missouri and around […]
Several blood tests used to diagnose Alzheimer’s disease are less accurate for African Americans than white patients, according to research from Washington University. The gold standard for Alzheimer’s diagnosis typically involves brain imaging and spinal fluid testing, but in recent years, biotech companies have developed an array of cheaper, less invasive blood tests to detect […]